Upgrade to SI Premium - Free Trial

RBC on Regeneron Pharma (REGN):'The Buying Opportunity Many Have Been Looking For, With Overdone DOJ Downside On Top Of Recent Weakness'

April 11, 2024 11:40 AM
RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $1,189.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments

Next Articles